BioMérieux

Beckman Coulter got regulatory clearance for three in vitro diagnostic products, including its DxH 520 hematology analyzer for low-volume clinical labs.

Value-Dx is being spearheaded by six in vitro diagnostic firms and 20 non-industry partners and will be funded with with €14 million over four years.

The firms will focus on developing and implementing biomarker-based immunoassay diagnostics for kidney injury. 

The firm also reported full-year 2018 sales of €2.42 billion, a year-over-year increase of 6 percent on a reported basis, or 10 percent organically.

The BioFire FilmArray Pneumonia panel will be used to optimize clinical trial enrollment for an antibiotic to treat combat carbapenem-resistant A. baumannii infections.

GenMark got clearance for an assay to detect fungal pathogens from blood cultures of patients with suspected bloodstream infections, and it received clearance for a bacterial assay.